Fresh analysis indicates that people who stop using blockbuster slimming jabs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop traditional diet and exercise plans.
Findings released in a major medical journal demonstrates that while obese individuals often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals buying such treatments should be informed of the risk of fast weight regain when the therapy ends," warns expert Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment weight in about a year and a half.
Analyzing Approaches
The research, which looked at 37 of studies involving thousands of participants, compared the results of the injectable medications with older methods.
The team point out that individuals who lose weight through dieting usually have a more gradual weight regain—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts believe the way of the drugs explains the accelerated regain.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is uncontrolled, making overeating far more likely."
A Chronic Disease?
The NHS advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, considering the significant potential of weight regain, the treatment is often life-long.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
People who have stopped the jabs describe a powerful return of cravings.
"It was like something activating and you're instantly starving," said a patient.
The struggle is worsened if users have not adopted permanent dietary or behavioural modifications during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on ongoing behavioural management.
